Nantahala Capital Management LLC bought a new stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 5,602,021 shares of the company’s stock, valued at approximately $38,878,026. Evolus comprises 0.0% of Nantahala Capital Management LLC’s portfolio, making the stock its 11th biggest position. Nantahala Capital Management LLC owned approximately 0.08% of Evolus as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new position in Evolus in the second quarter valued at approximately $33,595,000. Caligan Partners LP raised its stake in shares of Evolus by 23.8% during the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after purchasing an additional 796,973 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Evolus by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock valued at $21,054,000 after buying an additional 110,693 shares during the last quarter. Braidwell LP acquired a new stake in shares of Evolus in the 4th quarter valued at approximately $20,650,000. Finally, Soleus Capital Management L.P. grew its stake in shares of Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after buying an additional 1,039,842 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.
Wall Street Analysts Forecast Growth
EOLS has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. BTIG Research reiterated a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Evolus in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.50.
Evolus Stock Performance
Shares of NASDAQ EOLS opened at $8.88 on Friday. The company has a market capitalization of $586.52 million, a P/E ratio of -17.08 and a beta of 1.35. Evolus, Inc. has a 12 month low of $3.86 and a 12 month high of $9.12. The stock has a 50 day moving average of $7.04 and a 200-day moving average of $5.91.
Evolus Company Profile
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Featured Articles
- Five stocks we like better than Evolus
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS – Free Report).
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
